Literature DB >> 28866073

National trends in radiotherapy for brain metastases at time of diagnosis of non-small cell lung cancer.

Daniel M Trifiletti1, Jason P Sheehan2, Surbhi Grover3, Sunil W Dutta4, Chad G Rusthoven5, Brian D Kavanagh5, Arjun Sahgal6, Timothy N Showalter4.   

Abstract

BACKGROUND: To analyze the national trends of patients treated radiotherapy for brain metastases from non-small cell lung cancer (NSCLC) that were found at diagnosis.
METHODS: The National Cancer Database was queried for patients with NSCLC diagnosed from 2004 to 2013 that received brain irradiation for metastases and patients grouped into having had received fractionated brain radiotherapy (5-15 fractions with or without radiosurgery) or intracranial radiosurgery alone (1-5 fractions). Univariable and multivariable (MVA) analyses were performed to investigate factors associated with the receipt of SRS alone, and temporal/regional trends.
RESULTS: 47,746 patients met inclusion criteria, of which 42,148 received fractionated brain irradiation (88%) and 5,598 received radiosurgery (12%). 345 patients received fractioned brain irradiation with a radiosurgical boost (0.8%). The utilization of radiosurgery-alone increased over time owing to increases in each radiosurgery modality. On MVA, several factors were associated with increased odds of receiving intracranial radiosurgery-alone over fractionated brain radiotherapy including more recent year of diagnosis, increased median income, eastern U.S. regions, further distance to the hospital, and the receipt of chemotherapy (each p<0.001). Patients of Asian descent were less likely to receive radiosurgery alone (p=0.044).
CONCLUSIONS: In the management of brain metastases from NSCLC, overall utilization of an intracranial radiosurgery alone treatment strategy has increased over the past decade. Despite this, there appear to be significant geographic variations and disparities remain based on patient income level and race. Further study is needed to define the reasons for these disparities and appropriate actions to mitigate them.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brain; Lung cancer; Metastases; NCDB; Radiosurgery

Mesh:

Year:  2017        PMID: 28866073     DOI: 10.1016/j.jocn.2017.08.028

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  17 in total

1.  Disparities in the use of stereotactic radiosurgery for the treatment of lung cancer brain metastases: a SEER-Medicare study.

Authors:  Mustafa S Ascha; Kaitlyn Funk; Andrew E Sloan; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Clin Exp Metastasis       Date:  2019-11-08       Impact factor: 5.150

2.  MRI-based radiosurgical planning: implications in imaging timing.

Authors:  William C Stross; Timothy D Malouff; Daniel M Trifiletti; Laura A Vallow
Journal:  Ann Transl Med       Date:  2019-09

3.  Leptomeningeal disease following local brain irradiation: a new frontier.

Authors:  Daniel M Trifiletti; Paul D Brown
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

4.  Impact of socio-economic factors on radiation treatment after resection of metastatic brain tumors: trends from a private insurance database.

Authors:  David Y A Dadey; Adrian Rodrigues; Ghani Haider; Erqi L Pollom; John R Adler; Anand Veeravagu
Journal:  J Neurooncol       Date:  2022-05-21       Impact factor: 4.130

Review 5.  The Cognitive Effects of Radiotherapy for Brain Metastases.

Authors:  Eric J Lehrer; Brianna M Jones; Daniel R Dickstein; Sheryl Green; Isabelle M Germano; Joshua D Palmer; Nadia Laack; Paul D Brown; Vinai Gondi; Jeffrey S Wefel; Jason P Sheehan; Daniel M Trifiletti
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

6.  Assessment of Risk of Xerostomia After Whole-Brain Radiation Therapy and Association With Parotid Dose.

Authors:  Kyle Wang; Kevin A Pearlstein; Dominic H Moon; Zahra M Mahbooba; Allison M Deal; Yue Wang; Stephanie R Sutton; Britni B Motley; Gregory D Judy; Jordan A Holmes; Nathan C Sheets; Mohit S Kasibhatla; Heather D Pacholke; Colette J Shen; Timothy M Zagar; Lawrence B Marks; Bhishamjit S Chera
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

7.  Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis.

Authors:  Desmond A Brown; Victor M Lu; Benjamin T Himes; Terry C Burns; Alfredo Quiñones-Hinojosa; Kaisorn L Chaichana; Ian F Parney
Journal:  Clin Exp Metastasis       Date:  2020-01-16       Impact factor: 5.150

8.  Acute neurologic toxicity of palliative radiotherapy for brain metastases in patients receiving immune checkpoint blockade.

Authors:  W Tristram Arscott; Simeng Zhu; John P Plastaras; Amit Maity; Michelle Alonso-Basanta; Joshua Jones
Journal:  Neurooncol Pract       Date:  2018-10-25

Review 9.  Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases.

Authors:  Eric J Lehrer; Heather M McGee; Jason P Sheehan; Daniel M Trifiletti
Journal:  J Neurooncol       Date:  2020-02-12       Impact factor: 4.130

10.  Intracranial motion during frameless Gamma-Knife stereotactic radiosurgery.

Authors:  Danushka S Seneviratne; Laura A Vallow; Austin Hadley; Timothy D Malouff; William C Stross; Steven Herchko; Deanna H Pafundi; Daniel M Trifiletti; Jennifer L Peterson
Journal:  J Radiosurg SBRT       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.